Germany's Merck offloads consumer health unit

19 April 2018
mergers-acquisitions-big

In an industry where consumer health businesses seem to change hands as often as drugs and dollars, Germany’s Merck KGaA (MRK: DE) was the latest drugmaker to be involved in a deal this week.

The company has signed an agreement to sell its global Consumer Health business to US consumer goods corporation Procter & Gamble (NYSE: PG) for approximately 3.4 billion euros ($4.2 billion).

Merck announced that the proceeds would support further deleveraging and increase flexibility to strengthen all three of its business sectors, including the pharma unit.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical